Background: Infliximab and vedolizumab infusions pose a burden to inflammatory bowel disease (IBD) patients due to the need to travel and take time from work. To minimize burden, home infusions are available for selected patients. We aimed to describe the population receiving home infliximab and vedolizumab infusions. Methods: We conducted a retrospective cohort study using the QuintilesIMS PharMetrics Claims Data from January 2010 to June 2016. We included patients ≥18 years who have 2 codes on separate days for Crohn’s disease (CD; 555/K50) or ulcerative colitis (UC; 556/K51). We used codes to identify infliximab (J1745) and vedolizumab infusions (J3490/J3590 and charge ≥$4500). Those who had home health services on the same day were the home infusion cohort. We compared home infusions to standard infusions with respect to disease, demographics, geography, insurance and cost. Results: We identified 1,096 CD and 539 UC patients receiving home infliximab compared to 8,392 CD and 3,718 UC patients receiving standard infusion. Infliximab home infusions were most prevalent in the West (Table 1) and stable over time (Table 2). There were significantly fewer urgent or emergent care visits 2 days after home infusion compared to standard infusion (1.4% versus 3.3%, p<0.01). The median charges for infliximab home infusion was $5,700 compared to $6,200 for standard infusion. We identified 90 CD and 48 UC patients receiving home vedolizumab compared to 256 CD and 183 UC patients receiving standard vedolizumab. Vedolizumab home infusions were most prevalent in the West (Table 1). There was insufficient evidence to suggest a difference in urgent or emergent care visits in the vedolizumab home infusion and standard infusion cohorts (2.2% versus 2.9%, p=0.77). The median charges for vedolizumab home infusion was $5,500 compared to $8,674 for standard infusion. Conclusion: Home infusions may be a safe and cost-effective method to decrease infusion burden for selected patients.
